TILInstil Bio, Inc.Healthcare · Biotechnologyas of 2026-09-16
Horizon

Issued 2026-09-16 at $7.18 · now $7.18 (2026-09-16, +0.0% since)

Based on its own history, a month from the 2026-09-16 close, TIL has typically landed between $4.45 and $9.72 — a range of −38.0% to +35.4% from the issuance price $7.18.

Range of outcomes in historically similar periods — not a price prediction. Ranges are scored publicly on /methodology.
  • Actual close
  • Typical path (median)
  • Middle 50% of outcomes
  • 90% range

1,358 overlapping 1 month windows · 2021-03-192026-08-17 · basis climatology · forecast (batch). Probability up 53.9% (90% CI 51.756.1%, ≈1,408 obs).

The cone is anchored at the 2026-09-16 issuance close ($7.18) — the price the forecast resolves against on 2026-10-15, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.

Where TIL has typically landed a month from the 2026-09-16 close of $7.18 — the range is history, not a prediction.

$4.45worst · -38.0%$9.72best · +35.4%
  • now $7.18 (+0.0%)
  • typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $6.71 (-6.6%)
  • middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $5.88$7.53
  • 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $4.45$9.72
Actual 1-month windows behind the coneiEvery overlapping 1-month window in this security's own price history was ranked by realized return; shown are the 3 worst and 3 best of 1,358 windows spanning 2021-03-19 to 2026-09-16. Not cherry-picked — these are the extremes of the full sample. Max drop / max rise are the deepest and highest points reached within each window. See /methodology.
StartReturnMax dropMax rise
3 worst
2022-10-28−75.2%−75.2%+0.0%
2022-11-14−73.7%−73.7%+1.2%
2022-11-15−72.5%−74.0%+0.0%
3 best
2024-08-16+557.1%+0.0%+557.1%
2024-08-15+534.0%−1.6%+534.0%
2024-08-14+514.8%−3.8%+514.8%

1,358 overlapping windows · 2021-03-192026-09-16 · not cherry-picked

Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.

iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~6 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.
Jan
60%
+6.5%
n=5
Feb
40%
+1.1%
n=5
Mar
20%
−9.0%
n=5
Apr
17%
−13.7%
n=6
May
33%
+12.2%
n=6
Jun
17%
−9.0%
n=6
Jul
50%
+4.2%
n=6
Aug
67%
+5.7%
n=6
Sep
17%
+54.3%
n=6
Oct
20%
−17.0%
n=5
Nov
20%
−20.7%
n=5
Dec
20%
−21.1%
n=5

Up-frequency and average month-over-month return · historical frequency, not a prediction

Reported insider & political trades

Every Form 4 the people closest to this company have filed with the SEC — plotted against the share price, aggregated by month, and shown with the gap between when each trade happened and when it was disclosed. A public record, not advice.

Share price & reported tradesMonthly open-market valueReporting lag — trade date to filing date2026-092026-082026-072026-062026-052026-042026-032026-022026-012025-122025-112025-102025-092025-08$32$72025-09-10: 2 insider sales, $702K — Laumas Sandeep …2025-09: 2 open-market sales, $702K↑ buys↓ salesdirector Laumas Sandeep — Sale on 2025-09-10, filed 2 days after the tradedirector Laumas Sandeep — Sale on 2025-09-10, filed 2 days after the trade
DatePersonRoleActionShares @ priceValueOwnership Δvs S&P 1mvs S&P 6mOwned afterFiling
2025-09-10Laumas SandeepdirectorSale17,539 @ $23.04$404K−58.5% of holding−12.9%−64.6%12,461Form 4 · filed 2 days after the trade
2025-09-10Laumas SandeepdirectorSale12,461 @ $23.88$298K−100.0% of holding−12.9%−64.6%0Form 4 · filed 2 days after the trade

The vs-S&P columns are a labeled look-back on what the stock did after each filing, measured against the index over the same window. Descriptive history, not a claim about the person or a reason to trade.

14 award / exercise / gift records — not counted as purchases

Awards, option exercises, gifts and tax-withholding disposals are shown separately and never counted as open-market purchases or sales — they carry no conviction information.

DatePersonRoleActionSharesOwned afterFiling
2026-06-11Gibson Neil WdirectorAward / grant06,500Form 4
2026-06-11McGaughy R Kent JrdirectorAward / grant6,5006,500Form 4
2026-06-11Matcham GeorgedirectorAward / grant6,5006,500Form 4
2026-06-11Binder GwendolyndirectorAward / grant6,5006,500Form 4
2025-09-10Laumas SandeepdirectorOption exercise17,00017,000Form 4
2025-09-10Laumas SandeepdirectorOption exercise13,00030,000Form 4
2025-09-10Laumas SandeepdirectorOption exercise17,00017,000Form 4
2025-09-10Laumas SandeepdirectorOption exercise13,00030,000Form 4
2025-05-28McGaughy R Kent JrdirectorAward / grant6,5006,500Form 4
2025-05-28Matcham GeorgedirectorAward / grant6,5006,500Form 4
2025-05-28Gibson Neil WdirectorAward / grant6,5006,500Form 4
2025-05-28Binder GwendolyndirectorAward / grant6,5006,500Form 4
2025-04-25Crouch BronsondirectorAward / grant105,157105,157Form 4
2025-04-25Laumas SandeepdirectorAward / grant44,85144,851Form 4

Source: SEC Form 4 filings. Each row links to its original filing.

Across 2012–2021, stocks where a CEO, C-suite officer, or director had recently made an open-market common-stock purchase ran about +28 bp per month above the universe average (n=34,268 stock-weeks). A historical tendency, not a prediction.

Congressional disclosures

No congressional trades disclosed for this company.

Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.